Long‐term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors
Long‐term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors
复制标题
典型霍奇金淋巴瘤幸存者心血管疾病死亡的长期风险
DOI：
10.1002/cncr.34375
复制
发表时间：
2022-07
期刊：
影响因子：
--
通讯作者：
Caiwen Ou
中科院分区：
文献类型：
--
作者：
Zhenxing Lu;Yintong Teng;Xiaodong Ning;Hao Wang;Weijing Feng;Caiwen Ou
背景：经典霍奇金淋巴瘤（cHL）患者心血管疾病（CVD）死亡率在随访期间的时间趋势尚不清楚。本研究旨在评估cHL患者的这种时间趋势。方法本多中心队列纳入1983 - 2015年间诊断为cHL的15889例患者，涵盖所有年龄段。分析了比例死亡率、考虑竞争风险的病因特异性死亡率累积发生率、标准死亡率和绝对超额风险。结果在I期和II期cHL患者中，分别在大约60个月和120个月的随访后，CVD的比例死亡率高于cHL。对于几乎所有的I期或II期疾病患者，随着时间的推移，CVD的累积死亡率超过了cHL和其他肿瘤的死亡率。近几十年来，cHL死亡风险急剧下降，但cHL患者CVD死亡风险下降相当缓慢，甚至在某些人群中保持不变。在几乎所有随访期间，I期或II期疾病患者的心血管疾病死亡率高于一般人群。I期患者的CVD绝对超额风险达到48.5。结论随着时间的推移，心血管疾病的死亡风险超过了cHL和其他肿瘤，成为I期或II期患者死亡的主要原因。应采取更有效的措施降低心血管疾病死亡风险。在I期和II期经典霍奇金淋巴瘤（cHL）患者中，分别在大约60个月和120个月的随访后，心血管疾病（CVD）的比例死亡率超过cHL。对于几乎所有的I期或II期疾病患者，随着时间的推移，CVD的累积死亡率超过了cHL和其他肿瘤的死亡率。在过去的几十年里，cHL的死亡率风险急剧下降，但cHL患者的CVD死亡率风险在某些人群中下降很慢，甚至没有变化。随着时间的推移，心血管疾病超过了cHL，成为主要的死亡原因。
Background The temporal trend of cardiovascular disease (CVD) mortality in patients with classic Hodgkin lymphoma (cHL) throughout follow-up remains unclear. This study aimed to assess this temporal trend in patients with cHL. Methods This multicenter cohort included 15,889 patients with cHL diagnosed between 1983 and 2015, covering all ages. The proportional mortality ratio, cumulative incidence of cause-specific mortality accounting for competing risk, standard mortality ratio, and absolute excess risk were analyzed. Results Among patients in stage I and stage II cHL, the proportional mortality ratio for CVD exceeded that for cHL, after approximately 60 or 120 months of follow-up, respectively. For almost all the patients with stage I or stage II disease, the cumulative incidence of CVD mortality exceeded that of cHL and other neoplasms over time. In recent decades, the risk of cHL mortality declined sharply, but the risk of CVD mortality among patients with cHL declined quite slowly or even remained unchanged among some populations. Patients with stage I or stage II disease experienced a higher risk of CVD mortality than the general population in almost all follow-up intervals. The absolute excess CVD risk among patients in stage I reached 48.5. Conclusions The risk of CVD mortality exceeded that of cHL and other neoplasms and became the leading cause of death over time, among patients with stage I or stage II disease. More effective measures should be taken to reduce the risk of CVD mortality. Lay summary Among patients with stage I and stage II classic Hodgkin lymphoma (cHL), the proportional mortality ratio of cardiovascular disease (CVD) exceeded that of cHL after approximately 60 or 120 months of follow-up, respectively. For almost all the patients with stage I or stage II disease, the cumulative incidence of CVD mortality exceeded that of cHL and other neoplasms over time. In the past several decades, the risk of cHL mortality declined sharply, but the risk of CVD mortality among patients with cHL declined quite slowly or even unchanged among some populations. CVD exceeded cHL and has become the leading cause of death over time.
登录
查看更多内容
影响因子：
39.2
作者：
M. M. Applefeld-M.;J. Cole;S. H. Pollock;F. Sutton;R. Slawson;R. Singleton;P. Wiernik
通讯作者：
M. M. Applefeld-M.;J. Cole;S. H. Pollock;F. Sutton;R. Slawson;R. Singleton;P. Wiernik
DOI：
10.1891/9780826121646.0002
发表时间：
2018-09
期刊：
Cancer Rehabilitation
影响因子：
--
作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
通讯作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
DOI：
10.1093/jnci/djaa194
发表时间：
2021-06-01
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
de Vries S;Schaapveld M;Janus CPM;Daniëls LA;Petersen EJ;van der Maazen RWM;Zijlstra JM;Beijert M;Nijziel MR;Verschueren KMS;Kremer LCM;van Eggermond AM;Lugtenburg PJ;Krol ADG;Roesink JM;Plattel WJ;van Spronsen DJ;van Imhoff GW;de Boer JP;Aleman BMP;van Leeuwen FE
通讯作者：
van Leeuwen FE
影响因子：
3.8
作者：
Gao J;Chen Y;Wu P;Wang F;Tao H;Shen Q;Wang S;Gong S;Zhang X;Zhou Z;Song X;Jia Y
通讯作者：
Jia Y
影响因子：
24
作者：
I. Krul;Annemieke W. J. Opstal-van Winden;C. Janus;L. Daniëls;Y. Appelman;A. Maas;S. de Vries;K. Jóźwiak;B. Aleman;F. V. van Leeuwen
通讯作者：
I. Krul;Annemieke W. J. Opstal-van Winden;C. Janus;L. Daniëls;Y. Appelman;A. Maas;S. de Vries;K. Jóźwiak;B. Aleman;F. V. van Leeuwen